PharmTech Drug Digest 11.20
News|Videos|October 5, 2026

PharmTech Weekly Roundup—October 2, 2026

Author(s)Susan Haigney

This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.

This week on PharmTech.com, accountability was discussed in a variety of ways. From AI systems, supply chains, and CMC decision-making, pharma is being pushed to prove it can catch its own mistakes before patients pay for them. This week’s stories show an industry trying to build correction loops into everything from algorithms to API sourcing.

In news this week, the FDA's approval of AbbVie's JUVMO (tavapadon) gives Parkinson's patients the first D1/D5 receptor agonist on the market, with trial data showing most patients held their levodopa dose steady far longer than is typical.

Merck's SVP George Addona frames the company's $2.13 billion deal for a preclinical KRAS G12D inhibitor as pipeline diversification, though the Shanghai-to-Merck tech transfer ahead puts cross-border manufacturing and FDA scrutiny of overseas trials squarely in focus.

Autumn Conference Coverage

In conference news, exhibitors are previewing what's new at CPHI Milan 2026, including a gene-to-GMP manufacturing platform from Shilpa Biologicals and AI-vision-equipped sterile filling lines from Steriline.

In his upcoming CPHI Milan panel presentation, USP's Michael Levy makes the case that digitalization and AI play different roles in a modern supply chain, with machine-readable standards doing the heavy lifting while AI stays in a decision-support role that keeps scientists in control.

PharmTech also interviewed, CPHI Milan keynote speaker, USP CEO Ronald T. Piervincenzi. Piervincenzi is urging manufacturers to stop waiting on policy headlines and start acting on supply chain resilience now, warning that one resilient supplier can't stop a shortage when the rest of the market isn't equally prepared.

And Azurity Pharmaceuticals CEO Ron Scarboro argues medication non-adherence should be treated as a formulation design flaw rather than a patient compliance failure, pushing teams to build usability into drug development from day one, in another preview of CPHI Milan.

Ahead of her AAPS PharmSci 360 panel, BMS's Swita Singh says the biggest obstacle to risk-based CMC strategy isn't the science but organizational risk tolerance, since teams keep adding "just in case" testing even when the data doesn't call for it.

A continued look at AI

In PharmTech’s continued coverage of AI in pharma, columnist Brian Drapeau draws a direct line from the 1937 Massengill sulfanilamide poisoning to today's AI safety gap, arguing that frontier models can produce correct outputs without being "correctable" the way GMP-regulated manufacturing is built to be.

On an installment of the AI Pulse Check series, Open Biopharma's Richard Jaenisch cautions against letting media narratives overstate what AI actually did in the Merck-Moderna INTerpath-001 personalized cancer therapy trial, pointing instead to the governance gaps still unresolved around its use.

On Manufacturing Intelligence, Richard Jaenisch unpacks what FDA's new rule swapping "animal tests" for "nonclinical tests" actually means for CMC teams, noting that many of the newly validated methods are themselves a quieter form of AI.

Taken together, this week's stories make the point that trust isn't earned by getting it right once, it's earned by building the systems that catch you when you don't.


Related to this article